

What is Claimed is:

1. The compound which is:

8-(2,4,6-trifluorophenyl)-4-(2,4-difluorophenyl)-2-(2-hydroxy-1-

5 hydroxymethylethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;

4,8-Bis-(2,4-difluoro-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-
pyrido-[2,3-d]-pyrimidin-7-one;

8-(2,4,6-trifluorophenyl)-4-(2-fluorophenyl)-2-(2-hydroxy-1-
hydroxymethylethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;

10 8-(2,4,6-trifluorophenyl)-4-(4-fluorophenyl)-2-(2-hydroxy-1-
hydroxymethylethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;

4-(2-fluoro-phenyl)-8-(2,4-difluoro-phenyl)-2-((S)-2-hydroxy-1-methyl-
ethylamino)-8H-pyrido-[2,3-d]-pyrimidin-7-one;

4-(2,4-Difluoro-phenyl)-8-(4-fluoro-phenyl)-2-((S)-2-hydroxy-1-methyl-
15 ethylamino)-8H-pyrido-[2,3-d]-pyrimidin-7-one;

4,8-Bis-(2,4-difluoro-phenyl)-2-(2-hydroxy-1-methyl-ethylamino)-8H-pyrido-[2,3-
d]-pyrimidin-7-one;

8-(2,4-Difluorophenyl)-4-(2-chloro-4-fluorophenyl)-2-(2-hydroxy-1-
hydroxymethylethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; or

20 8-(2,3-difluorophenyl)-4-(2,4-difluorophenyl)-2-(2-hydroxy-1-hydroxymethyl-
ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; or a pharmaceutically
acceptable salt thereof.

2. A pharmaceutical composition comprising an effective amount of a

25 compound according to Claim 1 and a pharmaceutically acceptable carrier or
diluent.

3. A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal
in need thereof, which method comprises administering to said mammal an effective
30 amount of a compound according to Claim 1.

4. The method according to Claim 3 wherein the CSBP/RK/p38 kinase
mediated disease is psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis,
rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis,
35 osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock,
endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria,
meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury,
asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory

- disease, chronic obstructive pulmonary disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and brain and renal reperfusion injury, congestive heart failure, coronary arterial bypass grafting (CABG) surgery, thrombosis, atherosclerosis, glomerular nephritis, chronic renal
5 failure, diabetes, diabetic retinopathy, macular degeneration, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenerative disease, muscle degeneration, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, influenza induced pneumonia, eczema, contact dermatitis, psoriasis, sunburn, or conjunctivitis.
- 10
5. A method of treating the common cold or respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus in a human in need thereof which method comprises administering to said human an effective amount of
15 a compound according to Claim 1.
6. The method according to Claim 5 wherein the respiratory viral infection exacerbates asthma, exacerbates chronic bronchitis, exacerbates chronic obstructive pulmonary disease, exacerbates otitis media, exacerbates sinusitis, or wherein the
20 respiratory viral infection is associated with a secondary bacterial infection, otitis media, sinusitis, or pneumonia.
7. The compound which is:
- 4-(2,4-difluoro-phenylamino)-6-(2,4,6-trifluorophenylamino)-2-methylsulfanyl-
25 pyrimidine-5-carbaldehyde;
- 4-(2,4-difluoro-phenyl)-6-(2,4-difluorophenylamino)-2-methylsulfanyl-
pyrimidine-5-carbaldehyde;
- 4-(2-fluorophenyl)-6-(2,4,6-trifluorophenylamino)-2-methylsulfanyl-
pyrimidine-5-carbaldehyde;
- 30 4-(4-fluorophenyl)-6-(2,4,6-trifluorophenylamino)-2-methylsulfanyl-
pyrimidine-5-carbaldehyde;
- 4-(2-fluorophenyl)-6-(2,4-difluorophenylamino)-2-methylsulfanyl-
pyrimidine-5-carbaldehyde;
- 4-(2,4-Difluoro-phenyl)-6-(4-fluorophenylamino)-2-methylsulfanyl-
35 pyrimidine-5-carbaldehyde;
- 4-(2,4-difluoro-phenyl)-6-(2,4-difluorophenylamino)-methylsulfanyl-
pyrimidine-5-carbaldehyde;
- 4-(2-chloro-4-fluorophenyl)-6-(2,4-difluorophenylamino)-2-methylsulfanyl-

pyrimidine-5-carbaldehyde; or
4-(2,4-difluorophenyl)-6-(2,3-difluorophenylamino)-2-methylsulfanyl-
pyrimidine-5-carbaldehyde.